Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 7/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | PPIB | P23284 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | PPIG | Q13427 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12273902 | 0.98 | CYP1A2 (0.51) | CYP1A2CYP3A4LMNAMAOACNR2 | |
| SCHEMBL665559 | 0.86 | CYP1A2 (0.53) | CYP1A2CYP3A4LMNAMAOACNR2 | |
| Hydrochloric Acid SCHEMBL27869694 | 0.85 | LMNA (0.46) | CYP1A2CYP3A4LMNAMAOACNR2 | |
| SCHEMBL6279399 | 0.85 | CNR2 (0.58) | CYP1A2CYP3A4CNR2RORCNPC1 | |
| SCHEMBL18053924 | 0.84 | CYP1A2 (0.51) | CYP1A2CYP3A4LMNAMAOACNR2 | |
| SCHEMBL940605 | 0.84 | LMNA (0.55) | CYP1A2CYP3A4LMNAMAOAPPIB | |
| SCHEMBL4115523 | 0.84 | CNR2 (0.53) | CYP3A4LMNACNR2RORCTSHR | |
| SCHEMBL15630699 | 0.83 | RORC (0.51) | CYP1A2CYP3A4LMNACNR2RORC | |
| SCHEMBL10169477 | 0.83 | LMNA (0.49) | CYP1A2CYP3A4LMNACNR2RORC | |
| SCHEMBL27625366 | 0.83 | PARP10 (0.50) | CYP1A2CYP3A4LMNAMAOACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637430-B2 | Interleukin-17 (IL-17) inhibitors | HITGEN INC. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4177249-B1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-113880766-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-113880767-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-1997021704-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021435-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| US-4720506-A | Immunomodulating agent | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1988-01-19 | — | — | US | disclosed |
| EP-0094599-B1 | USE OF AMINOPHENYLACETIC ACID DERIVATIVES FOR THE MANUFACTURE OF AN IMMUNOMODULATING MEDICAL PREPARATION | MITSUBISHI KASEI CORPORATION (JP) | 1987-04-01 | — | — | EP | disclosed |
| EP-0052296-B1 | GLUTAMINE DERIVATIVES USABLE FOR CURING IMMUNE DISEASES, METHODS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING SAID DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1984-06-27 | — | — | EP | disclosed |
| US-4439448-A | IMMUNOMODULATING ACTIVITY | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1984-03-27 | — | — | US | disclosed |
| EP-0094599-A1 | Use of aminophenylacetic acid derivatives for the manufacture of an immunomodulating medical preparation | MITSUBISHI KASEI CORPORATION (JP) | 1983-11-23 | — | — | EP | disclosed |
| US-4348399-A | Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives | AMERICAN CYANAMID COMPANY (US) | 1982-09-07 | — | — | US | disclosed |
| EP-0052296-A1 | Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-26 | — | — | EP | disclosed |
| US-3997669-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637430-B2 | Interleukin-17 (IL-17) inhibitors | IL17A, IL2, IL23R | CYP1A2 161/4885CYP3A4 203/4885LMNA 4233/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP1A2 4493/4885CYP3A4 4744/4885LMNA 1266/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | CYP1A2 274/4885CYP3A4 826/4885LMNA 4866/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CYP1A2 4503/4885CYP3A4 4744/4885LMNA 1246/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP1A2 4493/4885CYP3A4 4744/4885LMNA 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.